Press release
KalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive Officer
– Planned transition reflects evolution to commercial company with sebetralstat for HAE – – NDA filing remains on track for H1 2024; Europe and Japan filings
About this update from Kalvista Pharmaceuticals, Inc.
[{"type":"text","content":"\n– Planned transition reflects evolution to commercial company with sebetralstat for HAE –\n\n\n– NDA filing remains on track for H1 2024; Europe and Japan filings H2 2024 –\n\n\n CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--\nKalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that Benjamin L. Palleiko, the Company’s current President, CBO and CFO, has been appointed as Chief Executive Officer and a director of the Company, effective immediately. In conjunction, Andrew Crockett has submitted his resignation as CEO and a director of the Company. This appointment is the result of a planned transition as KalVista prepares to become a commercial entity following the success of the KONFIDENT Phase 3 trial for its program sebetralstat as the first potential oral, on-demand therapy for hereditary angioedema (HAE), with a planned US NDA filing in the first half of this year.\n\n\n“I welcome Ben to the CEO role at this critical time in KalVista’s development. His long tenure with the Company positions us for continued success and allows us to make this seamless transition,” said Brian J.G. Pereira, MD, Chairman of the KalVista Board of Directors. “We also thank Andy for his service to the Company over the years. We look forward to the Company’s continued growth as it prepares for the potential launch of the first new, on-demand therapy for HAE in almost a decade.”\n\n\n“I am excited to take leadership of KalVista as we move to our next phase, evolving into a commercial organization,” said Ben Palleiko, Chief Executive Officer of KalVista. “I thank Andy for all his contributions to the Company since he co-founded it in 2011 and am grateful for his support over the years we have worked together. Our recent positive Phase 3 data and successful financing place us in a strong position to make this transition at this time. I look forward to continuing to advance our plans for sebetralstat on an accelerated timeline as we seek to launch it broadly for the benefit of people worldwide who are living with HAE.”\n\n\nBen Palleiko joined KalVista in 2016 as Chief Financial Officer and has been instrumental in supporting the growth and funding of the Company during its evolution from...